{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-038436","form_type":"8-K","ticker":"VXRT","cik":"0000072444","company_name":"Vaxart, Inc.","filed_at":"2024-12-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.918483+00:00","generated_at":"2026-05-28T23:10:01.154211+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Vaxart secures $37.7M additional BARDA funding for oral COVID-19 vaccine trial","bullets":["Modification No. 4 increases allotted trial funding from ~$96.5M to ~$134.2M.","Additional $37.7M for mRNA comparator acquisition and clinical site readiness.","Total estimated ceiling raised by ~$4.6M to ~$460.7M.","Trial compares Vaxart's oral XBB COVID-19 vaccine to an FDA-approved mRNA vaccine."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-038436","json":"https://secwatch.observer/filing/0001437749-24-038436.json","markdown":"https://secwatch.observer/filing/0001437749-24-038436.md","text":"https://secwatch.observer/filing/0001437749-24-038436.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/72444/000143774924038436/0001437749-24-038436-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/72444/000143774924038436/vxrt20241227_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T23:10:01.154211+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}